{"nctId":"NCT03925727","briefTitle":"Tavilermide Ophthalmic Solution for the Treatment of Dry Eye","startDateStruct":{"date":"2019-03-28","type":"ACTUAL"},"conditions":["Keratoconjunctivitis Sicca","Dry Eye"],"count":623,"armGroups":[{"label":"1% Tavilermide ophthalmic solution","type":"EXPERIMENTAL","interventionNames":["Drug: Tavilermide ophthalmic solution"]},{"label":"5% Tavilermide ophthalmic solution","type":"EXPERIMENTAL","interventionNames":["Drug: Tavilermide ophthalmic solution"]},{"label":"Vehicle ophthalmic solution","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Tavilermide ophthalmic solution","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject-reported history of dry eye disease in both eyes for at least 6 months;\n* History of use of artificial tear eye drops for dry eye symptoms;\n* Total score of â‰¥40 on SANDE;\n* TFBUT;\n* Corneal fluorescein staining;\n* Lissamine green conjunctival staining;\n* Schirmer's test score.\n\nExclusion Criteria:\n\n* Have participated in a previous tavilermide (MIM-D3) study;\n* Have clinically significant slit lamp findings at Visit 1;\n* Have a history of lacrimal duct obstruction within 12 months of Visit 1;\n* Have an uncontrolled systemic disease;\n* Be a woman who is pregnant, nursing or planning a pregnancy;\n* Be a woman of childbearing potential who is not using an acceptable means of birth control;\n* Have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study;\n* Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 45 days prior to Visit 1.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Eye Dryness Score as Measured by the VAS","description":"The Visual Analog Scale (VAS) where subjects were asked to rate their eye dryness (OU) by placing a vertical mark on the horizontal line to indicate their current level of discomfort. 0 mm corresponds to \"No Discomfort,\" and 100 mm corresponds to \"Maximal Discomfort.\" The length of the assessment line is 100 mm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.1","spread":"1.64"},{"groupId":"OG001","value":"-20.6","spread":"2.66"},{"groupId":"OG002","value":"-16.5","spread":"1.67"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Total Corneal Fluorescein Staining as Measured by the NEI Scale","description":"The National Eye Institute (NEI) scale is a standardized grading system of 0-3 was used for each of the 5 areas on each cornea (central, superior, temporal, nasal, and inferior) . Grade 0 was specified when no staining is present. The maximum score was 15. Study eye is the 'worse eye', defined as the eye with worse (higher) score at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.6","spread":"0.17"},{"groupId":"OG001","value":"-2.3","spread":"0.28"},{"groupId":"OG002","value":"-2.1","spread":"0.17"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":261},"commonTop":["Instillation site pain"]}}}